Elicio Therapeutics announced promising results from its Phase 2 study of the cancer drug ELI-002 7P, with two of three patients maintaining complete responses for over eight months and persistent T-cell activity observed. Despite earlier Phase 2 trial setbacks, the company plans a new Phase 1 study combining ELI-002 7P with chemotherapy and an anti-PD-1 inhibitor in metastatic KRAS pancreatic cancer, aiming to boost immune response and treatment effectiveness. These findings could guide future development strategies and Phase 3 trials. The stock rose nearly 29% following the news.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
Visionstate Corp. has decided to pause its previously announced non-brokered private placement financing under the LIFE exemption, initially targeting $500,000 to $1,000,000. The company will use this time to reconsider the structure and timing of th...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Following a five-year antitrust lawsuit by Epic Games, Google will let Android users in the US download third-party apps directly from the Google Play Store starting July 22. This change comes after a court ruling that found Google's Play Store pract...
